GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Brookline Capital Acquisition Corp (NAS:BCACW) » Definitions » Minority Interest

Switch to:

BCACW (Brookline Capital Acquisition) Minority Interest : $0.00 Mil (As of Mar. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Brookline Capital Acquisition Minority Interest?

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.

Brookline Capital Acquisition's minority interest for the quarter that ended in Mar. 2022 was $0.00 Mil.

Brookline Capital Acquisition Minority Interest Historical Data

The historical data trend for Brookline Capital Acquisition's Minority Interest can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Brookline Capital Acquisition Minority Interest Chart

Brookline Capital Acquisition Annual Data

Trend

Dec20

Dec21

Minority Interest

-

-

Brookline Capital Acquisition Quarterly Data
	Jun20	Sep20	Mar21	Jun21	Sep21	Dec21	Mar22
Minority Interest	Get a 7-Day Free Trial			-	-	-	-	-

Brookline Capital Acquisition Minority Interest Calculation

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.

Brookline Capital Acquisition Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Brookline Capital Acquisition Corp (NAS:BCACW) » Definitions » Minority Interest

Comparable Companies

Traded in Other Exchanges

N/A

Address

280 Park Avenue, Suite 43W, New York, NY, USA, 10017

Website

https://www.brooklinecapitalacquisitioncorp.com

Brookline Capital Acquisition Corp is a blank check company.

Brookline Capital Acquisition Headlines

From GuruFocus

Apexigen Announces Nature Medicine Publication and ASCO Presentation on the Phase 2 PRINCE Trial Showcasing Distinct Biosignatures in Metastatic Pancreatic Cancer Patients Treated with Sotigalimab and/or Nivolumab in Combination with Chemotherapy

By GuruFocusNews GuruFocusNews • 06-06-2022

Moore Kuehn Encourages VCKA, RNER, BCAC, and SUMR Investors to Contact Law Firm

By PRNewswire PRNewswire • 03-24-2022

Apexigen Appoints William Duke as Chief Financial Officer

By GuruFocusNews GuruFocusNews • 06-18-2022

Apexigen Announces Nature Medicine Publication and ASCO Presentation on the Phase 2 PRINCE Trial Showcasing Distinct Biosignatures in Metastatic Pancreatic Cancer Patients Treated with Sotigalimab and/or Nivolumab in Combination with Chemotherapy

By GuruFocusNews GuruFocusNews • 07-06-2022

Apexigen Appoints William Duke as Chief Financial Officer

By GuruFocusNews GuruFocusNews • 06-28-2022

Brookline Capital Acquisition Corp. Announces the Separate Trading of its Common Stock and Warrants, Commencing February 22, 2021

By Marketwired Marketwired • 02-18-2021

Brookline Capital Acquisition Corp. Announces the Separate Trading of its Common Stock and Warrants, Commencing February 22, 2021

By GlobeNewswire GlobeNewswire • 02-18-2021

Apexigen to Participate in the Brookline Capital Markets Newport Symposium

By PurpleRose PurpleRose • 07-11-2022

Apexigen and Brookline Capital Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Immuno-oncology Company

By GuruFocusNews GuruFocusNews • 03-18-2022

Apexigen Announces Nature Medicine Publication and ASCO Presentation on the Phase 2 PRINCE Trial Showcasing Distinct Biosignatures in Metastatic Pancreatic Cancer Patients Treated with Sotigalimab and/or Nivolumab in Combination with Chemotherapy

By GuruFocusNews GuruFocusNews • 06-16-2022

Home About Jobs Site Map Term of Use Privacy Policy Mobile App Referral Program Partner Program FAQ Contact Us 中文 All-In-One Screener
Stock List Guru List Insider List Insider Trade Economic Indicators Industry Data DCF Calculator Discussion Board Plans Excel Add-In Google Sheets Add-on
© 2004-2025 GuruFocus.com, LLC. All Rights Reserved.
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.